In this study, we explored whether ctDNA analysis could serve as a credible alternative for tumor genomic profiling in lung adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC), and whether the poor therapeutic response to EGFR-TKIs is associated with types and distributions of TP53 mutations. Here, TP53 is linked to neoplasm.